Results 221 to 230 of about 240,123 (312)

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
We conducted a nationwide, multicenter cohort study using a target trial emulation framework to compare baclofen and acamprosate in patients with compensated alcohol‐associated cirrhosis. After matching, baclofen initiation was associated with a higher 1‐year risk of major adverse liver outcomes, driven primarily by hepatic encephalopathy, particularly
Yee Hui Yeo   +13 more
wiley   +1 more source

Correction: Cannabis-based extract for managing pain in dogs with osteoarthritis: efficacy and safety assessment

open access: yesFrontiers in Pharmacology
Neide Maria Griebeler   +12 more
doaj   +1 more source

A qualitative investigation of the lived experiences of adults with anxiety and related disorders and ADHD: Interconnectedness of symptoms and implications for improving care

open access: yesBritish Journal of Clinical Psychology, EarlyView.
Abstract Background Attention‐deficit/hyperactivity disorder (ADHD) is highly prevalent in adults with anxiety and related disorders (ARDs). Quantitative research on this clinical population is mixed, with some studies suggesting that anxiety is protective against some symptoms of ADHD and others in which co‐occurring ARDs and ADHD are linked to poorer
Arij Alarachi   +3 more
wiley   +1 more source

Retrospective Event-Level Patterns of Cannabis-Impaired Driving. [PDF]

open access: yesJ Stud Alcohol Drugs
Teeters JB, Traxler SM, Harris F.
europepmc   +1 more source

The Australia story: Current status and future challenges for the clinical applications of psychedelics

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt   +3 more
wiley   +1 more source

Implementation of a Standardized Management Algorithm for Cannabis Hyperemesis Syndrome in a Pediatric Emergency Department. [PDF]

open access: yesPediatr Emerg Care
Kelly CM   +5 more
europepmc   +1 more source

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology

open access: yesBritish Journal of Pharmacology, EarlyView.
Theorized mechanism of dopamine homeostasis restoration in the nucleus accumbens core induced by a psychedelic intervention. Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive ...
Lucas Wittenkeller   +3 more
wiley   +1 more source

Variations in Regulated Cannabis Sales Conditions and Their Effect on Purchase Behaviour: Findings from an Observational Study.

open access: yesEur Addict Res
Heckel N   +7 more
europepmc   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

open access: yesBritish Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy